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Background: Diabetes during pregnancy can lead to severe risks for both mother and fetus when it is not
managed properly. The use of rigorously developed guidelines with a robust implementation process can have a
positive influence on the management of diabetes during pregnancy. This study aims to compare
recommendations and assess the quality of clinical guidelines on gestational diabetes mellitus (GDM) and
pre-existing diabetes mellitus during pregnancy.
Methods: Guidelines were selected by searching PubMed, the Guideline Clearing House and Google. All guidelines
developed since 2000 on diabetes during pregnancy in English or Dutch were considered. Recommendations of
the guidelines were compared. Furthermore, the quality was assessed by two authors independently, using the
AGREE instrument.
Results: Eight guidelines were included. According to the AGREE instrument, the quality of most guidelines was
low. The domains editorial independence, stakeholder involvement and rigour of development had the lowest
scores. Recommendations were mainly comparable on glycemic control, preconceptional counseling and prenatal
care and labour. Differences between recommendations were found for screening on GDM and induction of
labour.
Conclusions: The quality of most guidelines concerning the management of diabetes during pregnancy needs to
be improved. A more systematic approach in the development of these guidelines, more attention for updating
procedures and piloting of the guidelines and involvement of target users and patients is recommended.
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Diabetes during pregnancy can lead to serious risks for
both mother and fetus [1]. The management of diabetes
differs between women with gestational diabetes mellitus
(GDM) and pregnant women with pre-existing diabetes
mellitus type 1 (DM1) or type 2 (DM2).
GDM develops often towards the end of the second
trimester [1]. Maternal risk factors for GDM are: a BMI
above 30 kg/m², history of unexplained intrauterine fetal
death, previous GDM or a macrosomic baby, family his-
tory of DM, polycystic ovarian syndrome and ethnicity.
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reproduction in any medium, provided the orMiddle Eastern origin have an increased risk of GDM
[2-4]. After delivery, GDM usually resolves. However,
both mother and child have an increased risk of devel-
oping DM2 later in life.
In the Netherlands, the prevalence of GDM is esti-
mated between 1-15%, depending on the study popula-
tion [5]. The highest prevalence is found in non-Dutch
women. Because of migration and the increasing preva-
lence of obesity, it is likely that the number of pregnan-
cies complicated by GDM will increase.
DM1 and DM 2 affect 1% of pregnancies, but this is
probably an underestimation [6]. Due to the increasing
prevalence of DM2 caused by obesity in a younger age
group, it is assumed that the prevalence of pregnancies
complicated by DM2 will increase as well.
The possible complications due to diabetes during
pregnancy are severe. The mother has an increased riskLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and micro-vascular diseases such as retinopathy,
nephropathy and neuropathy [7]. In addition, there is an
increased risk for miscarriage, still birth, congenital
defects and neonatal morbidity and death [8]. For con-
genital defects, a dose-response relation is found: the
poorer the periconceptional blood glucose control, the
greater is the risk on congenital defects [9]. Another
major complication is macrosomia, which is a risk factor
for instrumental delivery, caesarean section, shoulder
dystocia during delivery and neonatal hypoglycemia dir-
ectly after birth [10].
There is strong evidence that proper management of
GDM and pre-existing DM during pregnancy leads to bet-
ter health outcomes for both mother and child [1,11]. To
ensure proper management, several guidelines from differ-
ent countries, institutes and organisations concerning the
management of diabetes during pregnancy have been pub-
lished. In general, guidelines are important instruments
for improving the quality of health care. They should be
based on the best available evidence and should also take
patient preferences and clinical experience into account
[12]. Furthermore, an effective strategy for the implemen-
tation of recommendations is an important next step for
realising proper management.Table 1 Domains and Items of the AGREE Instrument
AGREE Domain AGREE Item
Scope and purpose The overall objective of the
The clinical question covered
The patients to whom the g
Stakeholder involvement The guideline development
The patients’ view and prefe
The target users of the guid
The guideline has been pilo
Rigour of development Systematic methods were us
The criteria for selection of t
The methods used for formu
The health benefits, side effe
There is an explicit link betw
The guideline has been exte
A procedure for updating th
Clarity and presentation The recommendations are s
The different options for the
Key recommendations are e
The guideline is supported w
Applicability The potential organizational
The potential cost implicatio
The guideline presents a key
Editorial independence The guideline is editorially in
Conflicts of interest of guideSo far, the quality of guidelines concerning diabetes in
pregnancy has not been established. Therefore, the aim of
this study was to assess the quality of guidelines on diabetes
during pregnancy by an internationally acknowledged in-
strument. In addition, the recommendations for the man-
agement of diabetes during pregnancy were compared.
Methods
Selection of guidelines
To identify relevant clinical guidelines, the database of
PubMed (Medline) was searched up to October 2011
using the following terms: diabetes, gestational diabetes
and pregnancy and limited by ‘clinical guidelines’. Be-
cause guidelines are often not published in medical jour-
nals, the search was extended to the Internet by
screening the Guideline Clearing House and Google.
When searching these databases, the following terms
were used: clinical guidelines, diabetes, gestational dia-
betes and pregnancy. The authors checked the links in
Google until saturation was reached.
To be included in this study, guidelines had to meet
the following criteria:
1) the patient group consisted of pregnant women with
GDM or pre-existing DM, 2) the guideline addressed the
management of GDM or pre-existing DM duringguideline is specifically described
by the guideline is specifically described
uideline is meant to apply are specifically described
group includes individuals from all relevant professional groups
rences have been sought
eline are clearly defined
ted among target users
ed to search for evidence
he evidence are clearly described
lating recommendations are clearly described
cts and risks have been considered in formulating the recommendations
een recommendations and supporting evidence
rnally reviewed by experts prior to its publication
e guideline is provided
pecific and unambiguous
management of the condition are clearly presented
asily identifiable
ith tools for application
barriers in applying the recommendations have been discussed
ns of applying the recommendations have been considered
review criteria for monitoring and/or audit purposes
dependent from the funding body
line development members have been recorded
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guideline concerned Western populations and 5) the
guideline was available in the English or Dutch language.
Guidelines were excluded if they focused on the man-
agement of diabetes mellitus in general and did not in-
clude pregnant subjects. Furthermore, reports that
provided reviews on guidelines but did not contain spe-
cific recommendations were excluded, as well as guide-
lines that were developed before 2000 or that had not
been updated in the last 10 years.Quality assessment
Two reviewers independently assessed the quality of the
guidelines by using the English version of the AGREE in-
strument [12]. The AGREE instrument consists of 23
items in six domains (Table 1), which includes: 1) scope
and purpose of the guideline, 2) stakeholder involve-
ment, 3) rigour of development, 4) clarity and presenta-
tion, 5) applicability and 6) editorial independence.
Each item was assessed on a 4-point scale: 1 = strongly
disagree; 2 = disagree; 3 = agree and 4 = strongly agree.
The additional information in the AGREE guide was
used in order to clarify and correctly interpret each item.
Differences between the scores on positive and negative
assessment (e.g. scoring 1 or 2 vs. 3 or 4) of the two
reviewers were resolved in a consensus meeting. Finally,
domain scores were calculated by dividing the differ-
ences between the obtained score and the minimum
possible score by the difference between the maximum
possible score and the minimum possible score. In line
with similar studies, we defined scores of 50% or less as
low quality [13,14].Table 2 Domain Scores of the guidelines (percentages)
GuidelineComparison of guidelines
Two reviewers individually summarized four guidelines
each. Focus of the summaries was on recommendations.
Each summary was checked by the other reviewer on clarity
and completeness. One reviewer independently compared
the recommendations of all summaries and the other re-
viewer examined if these comparisons were correct.Agree Domain 1 2 3 4 5 6 7 8
Scope and purpose 67 56 39 33 28 61 67 94
Stakeholder involvement 17 8 42 4 14 21 8 100
Rigour of development 48 29 38 12 31 31 38 93
Clarity and presentation 67 71 75 50 83 63 71 100
Applicability 44 56 56 33 39 56 94 89
Editorial independence 0 0 42 0 0 8 50 50
1, American College of Obstetricians and Gynecologists, 2005. 2, American
Diabetes Association, 2003 & 2008. 3, Australasian Diabetes in Pregnancy
Society, 2002 & 2005. 4, British Columbia Reproductive Care Program, 2001. 5,
Colorado Clinical Guidelines Collaborative, 2006. 6, Dutch Society of Obstetrics
and Gynaecology, 2010. 7, International Diabetes Federation, 2009. 8, National
Institute for Clinical Excellence, 2008.Results
Four guidelines were identified in PubMed, four in the
Guideline Clearing House and seven in Google. Guide-
lines were excluded for different reasons; the guideline
of the International Diabetes Center [15] was excluded
because this guideline was similar to the guideline of the
American Diabetes Association [16,17]. Other guidelines
were excluded because they did not concern Western
populations [18], did not focus on diabetes in pregnancy
[19,20] or because of publication date [21,22].
Eight guidelines were included in this study, namely:1) American College of Obstetricians and Gynecologists
(ACOG) [23]
2) American Diabetes Association (ADA), GDM [16]
and pre-existing DM [17]
3) Australasian Diabetes in Pregnancy Society (ADIPS),
GDM [24] and pre-existing DM [25]
4) British Columbia Reproductive Care Program
(BCRCP) [26,27]
5) Colorado Clinical Guidelines Collaborative (CCGC)
[28]
6) Dutch Society of Obstetrics and Gynaecology (DSOG)
[29]
7) International Diabetes Federation (IDF) [30]
8) National Institute for Clinical Excellence (NICE) [31]Quality assessment
There was a high level of agreement between the two in-
dependent reviewers. In general, the quality of most
guidelines was questionable when using the AGREE in-
strument. The domains with the highest scores were ap-
plicability, clarity and presentation and scope and
purpose. The domains editorial independence, stake-
holder involvement and rigour of development had the
lowest scores. The domain scores of each guideline are
shown in Table 2.
The majority of the guidelines described their scope
and purpose quite specific. Four guidelines adequately
described both objectives and patient groups [16,17,29-
31]. In the other guidelines description of objectives was
incomplete [23-28]. Moreover, specific clinical questions
were only provided by the NICE guideline [31].
Regarding stakeholder involvement, seven guidelines
scored below 50%. Patients’ view and preferences were
often not included in the development of the guideline.
Moreover, the guidelines had not been piloted among tar-
get users, with the exception of the NICE guideline [31].
Seven guidelines had a low score on rigour of develop-
ment. This was mainly because most guidelines did not
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summarized the available evidence. Also information on
updating was not reported adequately in most guide-
lines; only the NICE guideline [31] provided a procedure
for updating.
In contrast, except for the guideline from the BCRCP
[26,27], all guidelines provided information on health
benefits, side effects or adverse effects. In addition, most
guidelines provided an explicit link between recommen-
dations and evidence by references or a summary of the
evidence. Only the CCGC guideline [28] did not provide
adequate information on the relation between evidence
and recommendation.
Regarding clarity and presentation, seven guidelines
scored over 50%. Key recommendations were easily
identifiable and different options for management were
given. It should be noted that only the CCGC guideline
[28] and NICE guideline [31] were supported with tools
for application, such as a quick reference guide.
On applicability, five guidelines scored over 50%. All
guidelines presented key review criteria for monitoring
and/or audit purposes. Considerations on costs or add-
itional resources were described by four guidelines
[16,17,24,25,30,31]. The guidelines of the DSOG [29],
IDF [30] and NICE [31] also provided information on
potential organizational barriers.
Regarding editorial independence, all eight guidelines
scored at or below 50%. Five guidelines did not report
anything on both independency of funding body and
conflicts of interest [16,17,23-25,28,29]. The other three
guidelines only fulfilled one of the two items
[26,27,30,31].Comparison of recommendations on management of
diabetes during pregnancy
The recommendations in the guidelines can be divided
into four domains, namely screening for GDM, glycemic
control, prenatal care and labour and preconception
counselling for women with DM1 or 2. The similarities
and differences between the different guidelines on each
domain will be discussed.
The first domain is screening for GDM. The recom-
mendations in this domain were inconsistent. Three
guidelines recommended that all pregnant women
should be screened [24,25,28,30]. On the other hand,
four guidelines recommended that only women with risk
factors should be screened [16,17,26,27,29,31]. However,
some guidelines refined their recommendation. The
ADIPS guideline [24,25] stated that selective screening
should be used when resources are limited. Furthermore,
the IDF guideline [30] stated that when the effectiveness
of selective screening is shown, this should be
recommended.Not all guidelines were explicit about what screening
criteria to use and at what time the screening should
take place. Regarding the screening criteria, two guide-
lines stated that the Coustan & Carpenter criteria should
be used [26-28] and one guideline [24,25] recommended
modified WHO-criteria. Concerning the time of screen-
ing, the BCRCP guideline [26,27] stated that it is not im-
portant to screen early while the CCGC guideline [28]
distinguished between women with and without risk fac-
tors. Women with risk factors should be screened as
early in pregnancy as possible. For women without risk
factors, early screening is not necessary.
The second domain is glycemic control. All guidelines
made similar recommendations such as, among others;
 Use a multidisciplinary approach that is adjusted to
the individual.
 Primary strategy is focused on nutrition and physical
activity.
 When glucose levels remain too high, medication
therapy should be started.
 Insulin is the primary choice; the use of
hypoglycaemic agents is discouraged.
 Blood glucose should be self-monitored regularly
and the importance of maintaining normal glucose
levels should be emphasized.
The third domain is prenatal care and labour. Two
recommendations were similar for most guidelines,
namely; 1) extra fetal surveillance is not necessary unless
there are complications and 2) during labour, it is im-
portant to maintain normal glucose values. Therefore,
glucose values should be monitored regularly.
Some guidelines made additional recommendations.
For example, the ADIPS guideline [24,25] stated that
after delivery, women with pre-existing DM should be
monitored closely to find a new balance. Furthermore,
some guidelines [16,17,23,29-31] stated that during pre-
natal care there should be searched for possible
complications.
However, there was one important difference between
the guidelines. Four guidelines recommended that deliv-
ery should not take place before full term unless there
are complications [23-28]. In contrast to this, three
guidelines stated that delivery should be induced after
approximately 38 weeks of gestation [16,17,29,31]. The
IDF guideline [30] did not make recommendations on
this topic.
The last domain is preconception counselling for
women with pre-existing DM. The recommendations in
this domain were similar for most guidelines. The first
recommendation was that all women with DM1 or 2 in
reproductive age should receive counselling. This coun-
selling should include information about the risks in
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tance of normal glucose values before conception should
be stressed [16,17,23-31]. Other recommendations in
this domain discussed the use of medication. Medication
that is used before conception, for example hypogly-
caemic agents, should be evaluated to determine if it is
safe during pregnancy [16,17,23-31]. In addition, it must
be checked if there are any complications, such as retin-
opathy, present before conception [16,17,23,29].
Discussion
The use of clinical guidelines is likely to have a positive
influence on the management of diabetes during preg-
nancy [1,11]. This article provides an overview of the
quality and content of clinical guidelines regarding the
management of diabetes during pregnancy. We reviewed
eight guidelines from six different countries. This study
shows that the overall quality of these guidelines was
low when using the AGREE instrument. Only two guide-
lines were found to be of moderate [30] or high quality
[31]. In general, the recommendations in several
domains were similar except for screening for GDM and
induction for delivery at term.
It is important that guidelines are of high quality. Accord-
ing to the AGREE instrument, most guidelines inadequately
reported on editorial independence, stakeholder involve-
ment and rigour of development. Especially the low score
on rigour of development is concerning, because explicit
descriptions of how the available evidence was identified
and selected is essential for the development of valid and
reliable evidence-based recommendations.
Also descriptions of the updating procedures of the
guidelines were poor, although it is important to keep
the recommendations based on the best available evi-
dence. Regarding stakeholder involvement, it might be
important that views and preferences of patients are
taken under consideration and that guidelines are
piloted among target groups. This may increase success
of implementation and thereby improve the manage-
ment of diabetes during pregnancy.
The low quality of most guidelines could be explained
by the fact that the AGREE instrument was not used by
the committees that were developing or updating the
guidelines. Only the committee of the NICE guideline
[31] used an instrument to asses the quality which is
part of their rigorous, standardized procedures. The use
of the AGREE instrument already showed to improve
the quality of other guidelines, such as guidelines on the
management of low back pain [14,32].
It should be noted that the score on the AGREE in-
strument does not only depend on the methodological
quality of the guideline, but also on the quality of report-
ing. It is possible that guidelines of high methodological
quality score low on the AGREE instrument due to poorreporting. One should bear this in mind while interpret-
ing the results of the current study. However, most
guidelines were published years after the AGREE instru-
ment was first published. One would assume that guide-
line developers are aware of the most up to date
discussions and literature about quality of developing
and quality of reporting guidelines.
Although there is some debate about using the AGREE
instrument for assessing the quality of guidelines and
about a 50% cut-off value, other papers on back pain
and acute gastroenteritis have used this approach before
[13,14]. Obviously, if the quality criteria were stricter,
then even fewer guidelines would be considered of good
quality, as shown in Table 2.
Regarding the recommendations, there were some dis-
crepancies between guidelines. These differences might be
a result of lack of evidence or weak associations. For ex-
ample, recommendations regarding screening on GDM in
the guidelines diverged as was also found in other studies
[33,34]. This diversity might be caused by equivocal evi-
dence on this topic in the period in which most guidelines
were developed [35]. Also consensus usually does not war-
rant similar recommendations because not only the avail-
able evidence but also other aspects such as costs,
applicability, constitution of the guideline committee and
ethical considerations influence recommendations.
Nonetheless, more variety between recommendations
was expected because of the variety in health care sys-
tems, culture in various countries and the differences in
membership of the guideline committees. Therefore,
current scientific evidence on the management of dia-
betes seems to be appropriate to generalize conclusions
to these different groups. Moreover, previous studies
also showed that international guidelines were consistent
in most of their recommendations, especially on precon-
ceptive care in women with diabetes [36].
The similarities between the guidelines included in this
study could partly be explained by the fact that they all
have been developed between 2001 and 2010. Moreover,
the recommendations of the ADA guideline [16,17] and
the CCGC guideline [28] were based mainly on the same
literature. Also some references of the IDF guideline [30]
were similar to those of the ADA [16,17] and the NICE
guideline [31]. In addition, the recommendations of the
guideline of the DSOG [29] were partially based on the
NICE guideline [31].
Conclusions
The quality of most guidelines on the management of dia-
betes during pregnancy can be improved. A more system-
atic approach in the development and reporting of these
guidelines is recommended. Extra attention for updating
procedures is advised. Also involvement of different health
care professionals and patients in the development and
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implementation. In addition, more attention for piloting
of guidelines is recommended. In order to obtain and
evaluate the improvements as described above, the
AGREE instrument can be a helpful tool.
However, guidelines of good quality do not ensure
good quality of management in daily practice. Therefore,
further research is important to develop efficient imple-
mentation strategies to increase appropriate uptake of
guideline recommendations by health care professionals.
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